| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 12/11/2003 | US20030228357 Sizing, compaction, forming tablets |
| 12/11/2003 | US20030228355 Precipitation of lipid; fineness particle size |
| 12/11/2003 | US20030228354 Drug in pressure sensitive adhesive |
| 12/11/2003 | US20030228348 Health food and preparation having an anti-obesity effect |
| 12/11/2003 | US20030228340 Applying pyridone/2-/, 1-hydroxy- |
| 12/11/2003 | US20030228320 Administering activator of retrovirus cells; then suppressor or destroying cells |
| 12/11/2003 | US20030228318 PSCA: prostate stem cell antigen and uses thereof |
| 12/11/2003 | US20030228314 Aminopeptidase inhibitor |
| 12/11/2003 | US20030228299 Using superoxide dismutase |
| 12/11/2003 | US20030228289 Universal chimera bank |
| 12/11/2003 | US20030228281 Use of mutant herpes viruses and anticancer agents in the treatment of cancer |
| 12/11/2003 | US20030228277 Reduce concentration of reactive oxygen metabolites |
| 12/11/2003 | US20030228273 Novel high viscosity embolizing compositions comprising prepolymers |
| 12/11/2003 | US20030228272 Mixture of antidanduff agent, surfactants, conditioning compound and oil |
| 12/11/2003 | US20030228265 Plant extracts; oral pathogens |
| 12/11/2003 | US20030228263 Propagermanium for treating myeloma bone disease and other bone disorders |
| 12/11/2003 | US20030228257 Induction apoptosis; antiarthritic agents |
| 12/11/2003 | CA2725704A1 Industrial process for preparing tropenol |
| 12/11/2003 | CA2706635A1 Camptothecins with a modified lactone ring |
| 12/11/2003 | CA2494451A1 Treatment of cell proliferative disorders with chlorotoxin |
| 12/11/2003 | CA2491420A1 Rb1 gene induced protein (rb1cc1) and gene |
| 12/11/2003 | CA2488287A1 Use of a synergistic combination of chlorogenic acid and 3-o-p-coumaryl quinic acid as an anti-leukemic therapy |
| 12/11/2003 | CA2488251A1 Novel solid preparation containing block copolymer and anthracycline anticancer agent and process for producing the same |
| 12/11/2003 | CA2488238A1 Method for reducing obstructive hydrocephalus |
| 12/11/2003 | CA2488048A1 Kinase suppressor of ras inactivation for therapy of ras mediated tumorigenesis |
| 12/11/2003 | CA2488013A1 Methods of using jnk or mkk inhibitors to modulate cell differentiation and to treat myeloproliferative disorders and myelodysplastic syndromes |
| 12/11/2003 | CA2488012A1 Cftr modifier genes and expressed polypeptides useful in treating cystic fibrosis |
| 12/11/2003 | CA2487923A1 Monotherapy for the treatment of amyotrophic lateral sclerosis with cyclooxygenase-2 (cox 2) inhibitor(s) |
| 12/11/2003 | CA2487918A1 3-descladinosyl-6-o-carbamoyl and 6-o-carbonoyl macrolide antibacterial agents |
| 12/11/2003 | CA2487915A1 Allergen from mugwort pollen |
| 12/11/2003 | CA2487905A1 Use of cgmp - stimulating compounds |
| 12/11/2003 | CA2487904A1 Immunostimulatory oligonucleotides and uses thereof |
| 12/11/2003 | CA2487885A1 Amyotrophic lateral sclerosis treatment with cyclooxygenase-2 inhibitors |
| 12/11/2003 | CA2487786A1 Dosage forms and compositions for osmotic delivery of variable dosages of oxycodone |
| 12/11/2003 | CA2487757A1 Porphyrin oxygen infusion preparation for increasing oxygen concentration in tumor tissue |
| 12/11/2003 | CA2487730A1 Sgk and nedd used as diagnostic and therapeutic targets |
| 12/11/2003 | CA2487724A1 Immunogenic sequences |
| 12/11/2003 | CA2487720A1 Therapeutic agent-containing polymeric nanoarticles |
| 12/11/2003 | CA2487679A1 Inhibitors of jak and cdk2 protein kinases |
| 12/11/2003 | CA2487678A1 Compositions for therapeutic use comprising a vitamin, a metal salt and insulin or a growth hormone |
| 12/11/2003 | CA2487675A1 Novel substituted indoles |
| 12/11/2003 | CA2487666A1 Anthelmintic and insecticidal thiophene derivatives |
| 12/11/2003 | CA2487639A1 Self-administered contraceptive injection of oily solution |
| 12/11/2003 | CA2487636A1 Flourinated cyclic amides as dipeptidyl peptidase iv inhibitors |
| 12/11/2003 | CA2487597A1 Bacterial transforming agent |
| 12/11/2003 | CA2487577A1 Implantable polymeric device for sustained release of buprenorphine |
| 12/11/2003 | CA2487509A1 New salts |
| 12/11/2003 | CA2487425A1 Combination chemotherapy with chlorotoxin |
| 12/11/2003 | CA2487293A1 Use of new etonogestrel esters |
| 12/11/2003 | CA2487171A1 Method for the protection of endothelial and epithelial cells during chemotherapy |
| 12/11/2003 | CA2487024A1 Control sequences of the human corin gene |
| 12/11/2003 | CA2486832A1 Pyranoindazoles and their use for the treatment of glaucoma |
| 12/11/2003 | CA2486530A1 2-oxo-1,3,4-trihydroquinazolinyl derivatives for the treatment of cell proliferation-related disorders |
| 12/11/2003 | CA2486424A1 Oil-soluble pigment compositions |
| 12/11/2003 | CA2486409A1 Policosanol compositions, extraction from novel sources, and uses thereof |
| 12/11/2003 | CA2486191A1 1-(aminoalkyl)-3-sulfonylazaindoles as 5-hydroxytryptamine-6 ligands |
| 12/11/2003 | CA2486174A1 Xanthine phosphodiesterase v inhibitor polymorphs |
| 12/11/2003 | CA2486110A1 Pharmaceutical combination |
| 12/11/2003 | CA2485932A1 Pharmaceutical composition containing oxcarbazepine and having a controlled active substance release |
| 12/11/2003 | CA2485871A1 1-(aminoalkyl)-3-sulfonylindole and -indazole derivatives as 5-hydroxytryptamine-6 ligands |
| 12/11/2003 | CA2485533A1 Immediate release pharmaceutical formulation |
| 12/11/2003 | CA2485355A1 The use of milnacipran for the treatment of tension-type headache |
| 12/11/2003 | CA2485194A1 Dietary method for modulating glucose metabolism and associated conditions and increasing longevity |
| 12/11/2003 | CA2485111A1 Topical use of at least one double-stranded rna oligonucleotide (ds rna) |
| 12/11/2003 | CA2485080A1 Pharmaceutical composition having a delayed active substance release, and method for the preparation thereof |
| 12/11/2003 | CA2484972A1 Personal care article and method for inhibiting attachment of yeast to skin |
| 12/11/2003 | CA2484451A1 Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof |
| 12/11/2003 | CA2483834A1 Norethindrone sustained release formulations and methods associated therewith |
| 12/11/2003 | CA2482838A1 Pyrazole compounds and pharmaceutical compositions containing the compound |
| 12/11/2003 | CA2482639A1 3-substituted quinuclidines and their use |
| 12/11/2003 | CA2482345A1 Compounds and compositions for the treatment of diabetes and diabetes-related disorders |
| 12/11/2003 | CA2480326A1 Knockout mice and their use |
| 12/11/2003 | CA2477261A1 Methods for enhancing motor performance and/or endurance |
| 12/11/2003 | CA2454654A1 Pharmaceutically active compounds having a tricyclic pyrazolotriazolopyrimidine ring structure and methods of use |
| 12/11/2003 | CA2431806A1 Compositions for cancer therapy |
| 12/11/2003 | CA2390290A1 Protopanaxadiol and protopanaxatriol and their use as anti-cancer agents |
| 12/10/2003 | EP1369490A1 Method of preparing a composition containing hygromycin A and epi-hygromycin |
| 12/10/2003 | EP1369483A1 Allergen from mugwort pollen |
| 12/10/2003 | EP1369432A2 Soluble highly branched glucose polymers and process for their preparation |
| 12/10/2003 | EP1369421A1 Pharmaceutical compositions comprising 2,3-Diaryl-pyrazolo[1,5-B]pyridazine derivatives |
| 12/10/2003 | EP1369420A1 Inhibitors of the GPib - vWF interaction |
| 12/10/2003 | EP1369419A1 N-phenylarylsulfonamide compound, drug containing the compound as active ingredient, intermediate for the compound, and processes for producing the same |
| 12/10/2003 | EP1369417A1 Acridine derivatives |
| 12/10/2003 | EP1369414A1 Enantiomerically pure Arylcycloalkyl hydroxycarboxylic esters, processes for their preparation and their use as modulators of muscarinic receptors |
| 12/10/2003 | EP1369409A1 Process for preparing compounds useful as intermediates |
| 12/10/2003 | EP1369133A1 Gene carriers with the use of polysaccharide and process for producing the same |
| 12/10/2003 | EP1369132A1 Oxaliplatin containing liposome preparation |
| 12/10/2003 | EP1369130A1 Process for producing sustained release preparation |
| 12/10/2003 | EP1369129A1 Remedies for depression containing ep1 antagonist as the active ingredient |
| 12/10/2003 | EP1369128A1 Inhibitors of glycoprotein VI and their therapeutic use |
| 12/10/2003 | EP1369122A1 Anticancer agent |
| 12/10/2003 | EP1369120A1 Treatment of flavivirus infection |
| 12/10/2003 | EP1369119A1 Il-12 expression controlling agents |
| 12/10/2003 | EP1369118A1 Process and agent for the prevention, inhibition and therapy of sepsis |
| 12/10/2003 | EP1369117A1 Use of derivatives and precursors of oxaziridine in the treatment of cancerous tumours |
| 12/10/2003 | EP1369116A1 Oxalatoplatin and 5-fluorouracil for combination therapy of cancer |
| 12/10/2003 | EP1369115A1 Methods of preventing breast cancer by the administration of Raloxifene |
| 12/10/2003 | EP1369114A1 Use of tryptophan metabolites as pharmaceutical agents |
| 12/10/2003 | EP1369112A1 Percutaneous absorption-type pharmaceutical preparation and process for producing the same |
| 12/10/2003 | EP1369106A1 Emulsion composition |